For instance, medications that help with the psychological effects of schizophrenia might also help with schizoid personality disorder. Stimulants, which are medications that energize people, and ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback